HP661

HP661 is a potent and selective mitochondrial complex I inhibitor that reduces viability in OXPHOS-high lung cancer cells (e.g., H460, A549) with nanomolar IC50s while sparing low-OXPHOS cells. It demonstrates significant in vivo antitumor activity in an H460 xenograft model and synergizes with trametinib, supporting its use in cancer metabolism and therapy resistance research.